U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H15NO8S2
Molecular Weight 437.444
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PICOSULFURIC ACID

SMILES

OS(=O)(=O)OC1=CC=C(C=C1)C(C2=CC=C(OS(O)(=O)=O)C=C2)C3=CC=CC=N3

InChI

InChIKey=UJIDKYTZIQTXPM-UHFFFAOYSA-N
InChI=1S/C18H15NO8S2/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)

HIDE SMILES / InChI

Molecular Formula C18H15NO8S2
Molecular Weight 437.444
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Picosulfuric acid (as sodium picosulfate) is a contact laxative, which is used in combination with: magnesium oxide, and anhydrous citric acid for cleansing of the colon as a preparation for colonoscopy in adults. Sodium picosulfate is a prodrug. It has no significant direct physiological effect on the intestine. But it is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PREPOPIK

Approved Use

PREPOPIK (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Launch Date

1.34231045E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.3 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
21.3 ng/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
209 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
275 ng × h/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
7.4 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Analytical control of a pharmaceutical formulation of sodium picosulfate by capillary zone electrophoresis.
2001 Feb 10
Retrospective study of long-term treatment with sodium picosulfate.
2004 Apr
Is bowel preparation required before cystoplasty in children?
2006 Oct
Interaction between Shaoyao-Gancao-Tang and a laxative with respect to alteration of paeoniflorin metabolism by intestinal bacteria in rats.
2007 Aug
Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy.
2007 Dec 3
Randomized clinical trial comparing sodium picosulfate with mannitol on the preparation FOR colonoscopy in hospitalized patients.
2007 Jul-Sep
A review of laxative therapies for treatment of chronic constipation in older adults.
2010 Dec
Laxative activities of Mareya micrantha (Benth.) Müll. Arg. (Euphorbiaceae) leaf aqueous extract in rats.
2010 Feb 16
Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.
2010 Sep
Patents

Sample Use Guides

PREPOPIK ((sodium picosulfate, magnesium oxide, and anhydrous citric acid), supplied as a powder, must be reconstituted with cold water right before its use. There are two dosing regimens, each requires two separate dosing times: The preferred method is the “Split Dose” method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy. The alternative method is the “Day Before” method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy). Additional fluids must be consumed after every dose in both dosing regimens. Instruct patients to consume only clear liquids (no solid food or milk) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy. Instruct patients that if they experience severe bloating, distention, or abdominal pain following the first dose, delay the second dose until their symptoms resolve.
Route of Administration: Oral
In Vitro Use Guide
Sodium picosulfate was biotransformed by intestinal flora that produced a novel sulfotransferase (not sulfatase). The biotransformation was activated by adding phenolic compounds such as phenol, acetaminophen and flavonoids. The enzyme activity related to this biotransformation was the highest in the contents of the caecum region of the intestine. The enzyme activity was 3.0 umole/hr/g wet feces in humans and 0.75 in rats (pH 8.0). The optimal pH was 9.0. The sulfotransferase activity was assayed in reaction mixture consisting of 60 uL of 50 mM PNS (occasionally sodium picosulfate), tyramine and 0.2 ml of the enzyme solution. Sulfatase activity was measured under the assay conditions for he sulfotransferase acitivity without the addition of the acceptor tyramine.
Substance Class Chemical
Created
by admin
on Thu Jul 06 07:57:47 UTC 2023
Edited
by admin
on Thu Jul 06 07:57:47 UTC 2023
Record UNII
95D580798S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PICOSULFURIC ACID
Common Name English
PICOSULFATE [VANDF]
Common Name English
PICOSULFATE
VANDF  
Common Name English
PHENOL, 4,4'-(2-PYRIDINYLMETHYLENE)BIS-, 1,1'-BIS(HYDROGEN SULFATE)
Common Name English
Classification Tree Code System Code
WHO-ATC A06AB58
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
Code System Code Type Description
RXCUI
1546457
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY RxNorm
SMS_ID
100000168459
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
RXCUI
1546458
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
CAS
10040-34-3
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
EPA CompTox
DTXSID70143251
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
EVMPD
SUB181842
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
PUBCHEM
5243
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
DRUG BANK
DB09268
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
FDA UNII
95D580798S
Created by admin on Thu Jul 06 07:57:47 UTC 2023 , Edited by admin on Thu Jul 06 07:57:47 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG